TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors. - Wikidata - wikimedia - TriplyDB

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.

http://www.wikidata.org/entity/Q37352827

about

Early effects of low dos C ion or X-ray irradiation on human peripheral blood lymphocytes Loss of expression of MHC class I-related chain A (MICA) is a frequent event and predicts poor survival in patients with hepatocellular carcinoma.CD4+NKG2D+ T cells exhibit enhanced migratory and encephalitogenic properties in neuroinflammation.Distinct signatures of the immune responses in low risk versus high risk neuroblastoma A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.Substantial increase in the frequency of circulating CD4+NKG2D+ T cells in patients with cervical intraepithelial neoplasia grade 1.Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors.Soluble MHC I and soluble MIC molecules: potential therapeutic targets for cancer.The immunoregulatory mechanisms of carcinoma for its survival and development Cancer stem cells: perspectives for therapeutic targeting.OMIP-029: Human NK-cell phenotypization.Regulation of the expression of the liver cancer susceptibility gene MICA by microRNAs.DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.Aging related changes of circadian rhythmicity of cytotoxic lymphocyte subpopulations.Resveratrol ameliorates ionizing irradiation-induced long-term immunosuppression in mice.Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.[Expression and clinical significance of CD8+natural killer T cell stimulatory receptor NKG2D in peripheral blood of lung cancer patients].Long-term survival of a patient with recurrent gallbladder carcinoma, treated with chemotherapy, immunotherapy, and surgery: a case report

P2860

Q33786099-6123F230-0C0B-4567-8B47-44658316B3F6 Q33898809-C49BDE42-72A8-46BE-AC81-0F0EC85F6C74 Q35055326-619F1CF7-4E4C-4464-803B-6FDC9AE3ABC7 Q35373780-62D7F027-F1A0-410A-9D63-77D109820978 Q35743874-A06A375D-9578-4695-A618-4DEE8C30BA71 Q36711007-9281A330-19D6-40D9-BCC9-ED5A115C5ABD Q37116995-D4164974-A800-4F70-BDF4-C95368EA2B2A Q37751873-D0764BFB-0E3A-4F3E-834C-E291EEE00349 Q37821374-840ACFEC-876E-4F23-A1F9-9E6FD516AE10 Q37828518-FA29C11F-5434-4A8A-898E-42FD107BB5CB Q37831426-A6C5AA2A-0DE3-4450-B315-2099145F859B Q38238005-B912BB9B-4EE8-4516-9326-E8039CFAEBA1 Q38557974-322A01ED-4CC1-4C94-95BE-FDE6FC76440C Q39092681-C71630B7-88B9-43B4-BFDD-805295EA5A57 Q39227235-916F29F1-2225-4475-9279-9C32FCD1627C Q41279994-365BB46C-006F-4227-9D0A-DD80F14DABA1 Q41869606-5D405060-AE9E-4159-A4EB-A8BC1624CAF3 Q48217931-61B83676-257F-4A11-9EEA-585473E6032C Q52758918-C85C1677-F065-4C81-B04B-8CE3D4AC8FA4 Q55444778-4123C116-A183-4E60-A7EE-4593394B21D4 Q58737764-BC58332C-1EA4-4935-A4EF-E934EA7454D2

P2860

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.

http://www.wikidata.org/entity/Q37352827

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.

@en

TNK cells

@nl

type

label

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.

@en

TNK cells

@nl

prefLabel

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.

@en

TNK cells

@nl

P1433

Q37352827-99CD6CF4-78A8-4785-A18D-935B3FDD8D42

P1476

Q37352827-A9AED7EE-5BF2-47B0-A4BE-F51CEA9921EC

P2093

Q37352827-24EBBC52-7E2C-4D72-9DB7-DEFB01AEB23C

Q37352827-529AC5A6-5AA1-4BC0-A0D7-D584D219C95F

Q37352827-BA6EA7F6-196F-4C0B-A9F1-D8707F799D21

P2860

Q37352827-05749B72-0E18-46BA-BB2A-F30D7D6EEA6F

Q37352827-2BF03F09-3DD7-41F2-8110-ABCA733F981D

Q37352827-3669B0A3-E1EE-4A3F-ACD3-1022BAFEA14B

Q37352827-3820C136-B90F-4E80-9DE7-41AB35F5D408

Q37352827-433C105E-0A03-48C2-9466-DED975391F21

Q37352827-59A70A62-8B69-4A8B-8F6B-C1F6C05B7B9F

Q37352827-6D7802CB-0B0D-42E1-983A-4BDF3D48EAE8

Q37352827-82A99D31-B64D-4104-A457-67B8CC3451E7

Q37352827-8A806FF5-326C-4965-8DEF-82CDFA5F6349

Q37352827-990EC3B3-38BB-470A-B8A6-CD744659A6EE

P2888

Q37352827-85717643-875C-4EE7-80F6-2B730477F7C1

P304

Q37352827-9922D23B-47DD-46A7-AE17-F76E4D21F539

P31

Q37352827-21E733B2-DAFD-47AC-8D26-183E467364C7

P356

Q37352827-AD39BE54-D7B1-4412-912F-9C7E5DA728EA

P433

Q37352827-5B52F5B3-99A5-49D1-BFEE-F2A9414CE73C

P478

Q37352827-E6DF8CFC-3A85-471B-B0A9-A8BB455530AA

P577

Q37352827-F2A3A982-30C6-4D49-B5E1-29BB238AAEB5

P5875

Q37352827-22D80549-C476-45BF-BB4A-308050CA6A13

P698

Q37352827-785EF2C2-304D-4037-9ECF-11A3B812B65C

P356

S00262-008-0635-X

P1433

Cancer Immunology, Immunotherapy

P1476

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.

@en

P2093

Cristina Maccalli

http://www.w3.org/2001/XMLSchema#string

Giorgio Parmiani

http://www.w3.org/2001/XMLSchema#string

Samantha Scaramuzza

http://www.w3.org/2001/XMLSchema#string

P2860

Going both ways: immune regulation via CD1d-dependent NKT cells.

Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D.

IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses.

Human tumor-derived exosomes down-modulate NKG2D expression.

Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity.

The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands.

Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis.

Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12.

Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.

Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.

P2888

s00262-008-0635-x

P304

801-808

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-008-0635-X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23670310

http://www.w3.org/2001/XMLSchema#string

P698

19089424

http://www.w3.org/2001/XMLSchema#string